Baxter International Inc. considering sale of hemodialysis and renal care businesses

Trending News ☀️

Baxter International($NYSE:BAX) Inc is considering the sale of its hemodialysis and renal care businesses, according to Bloomberg. The healthcare equipment maker earned favorable reviews from Bank of America and Well Fargo after the news was reported. Baxter has been exploring strategic options for its renal care business for some time, and a sale would allow the company to focus on its core businesses. The sale would also provide Baxter with much-needed cash to invest in growth initiatives. Bank of America and Well Fargo both see the potential sale as a positive move for Baxter. The sale would allow Baxter to focus on its core businesses and would provide the company with much-needed cash to invest in growth initiatives.

Stock Price

On Wednesday, shares of Baxter International Inc opened at $58.3 and closed at $59.1, up by 1.7% from prior closing price of $58.1. Baxter International Inc is a global healthcare company that develops and manufactures products for a wide range of therapeutic areas, including renal care. The company’s renal care business includes dialysis products and services, as well as renal transplantation products. The company has been exploring strategic options for its renal care business, and a sale is one of the options under consideration. There is no certainty that a sale will occur, and no timetable has been set for any potential transaction. Baxter International Inc is committed to providing innovative products and services that improve the quality of life for patients worldwide. The company will continue to evaluate strategic options for its businesses in order to create shareholder value.

VI Analysis

Baxter International is a strong company with a high health score of 7/10. It is capable of safely riding out any crisis without the risk of bankruptcy. The company is strong in dividend, profitability, and weak in asset, growth. Baxter International is classified as ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Due to its moderate growth rate, such company is deemed less risky and volatile as it pursuits a sustainable growth rate. For more details please visit Star Chart.

Summary

Baxter’s hemodialysis business provides treatments for patients with kidney failure and includes products and services for dialysis centers and home patients. The renal care business provides products and services to help patients manage kidney diseases. The sale of these businesses would be in line with Baxter’s strategy to focus on its core businesses of biopharmaceuticals and medical devices. The proceeds from the sale could be used to bolster Baxter’s other businesses or to repurchase shares. Investors should monitor the situation closely for any further developments.